Processa Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Processa Pharmaceuticals, Inc. (PCSA) had Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year of $23.35 thousand as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear · last filed 2025-08-07
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $23.35K.
- 2025-03-31: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $46.69K.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $23.35K.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $45.80K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2025-06-30 | $23.35K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $46.69K 10-Q · filed 2025-05-08 |
| 2024-09-30 | $23.35K 10-Q · filed 2024-10-30 |
| 2024-06-30 | $45.80K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $68.25K 10-Q · filed 2024-05-10 |
| 2023-09-30 | $24.11K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $47.35K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $70.60K 10-Q · filed 2023-05-15 |
| 2022-09-30 | $23.19K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $26.46K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $51.31K 10-Q · filed 2022-05-12 |
| 2021-09-30 | $24.80K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $48.78K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $72.75K 10-Q · filed 2021-05-13 |
| 2020-09-30 | $22.42K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $45.87K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $69.32K 10-Q · filed 2020-05-15 |
| 2019-09-30 | $23.40K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $48.45K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $73.51K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |